SCNI

6-K - Scinai Immunotherapeutics Ltd. (0001611747) (Filer)

JERUSALEM, Oct. 16, 2026 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (NASDAQ:SCNI) ("Scinai" or the "Company"), a biopharmaceutical company operating a growing contract development and manufacturing organization ("CDMO") alongside an immunology-focused therapeutic development platform, today announced the closing of its previously announced private placement of 2,458,334 American Depositary Shares ("ADSs") (or pre-funded warrants in lieu thereof), each ADS representing 40,000 ordinary shares, together with Series A-1 Warrants to purchase up to 3,687,501 ADSs (the "Private Placement"). In addition, the Company has closed the

6-K - Scinai Immunotherapeutics Ltd. (0001611747) (Filer)

JERUSALEM, October 14, 2026 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (NASDAQ:SCNI) ("Scinai" or the "Company"), a biopharmaceutical company operating a growing contract development and manufacturing organization ("CDMO") alongside an immunology-focused therapeutic development platform, today announced that it has entered into a securities purchase agreement with an existing life sciences institutional investor for the purchase and sale of 2,458,334 American Depositary Shares ("ADSs") (or pre-funded warrants in lieu thereof), each ADS representing 40,000 ordinary shares, together with Series A-1 warrants to purchase up to 3,687,501 ADSs, at an exercise price of $1.20 per ADS, exercisabl

6-K - Scinai Immunotherapeutics Ltd. (0001611747) (Filer)

Committed Customer Orders¹ reach approximately $7.6 million, up approximately 300% from $1.9 million at year-end 2025Agreement with a U.S. based, Nasdaq-listed biopharmaceutical company supports development activity in 2026 and clinical manufacturing planned for 2027Potential additional clinical manufacturing carries an indicative, uncommitted service-fee value of $5.85 million for late 2027 through the first half of 2028, excluding additional scale-up, qualification and initial manufacturing activities not yet pricedJERUSALEM, Oct. 13, 2026 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (NASDAQ:SCNI) ("Scinai" or the "Company"), a biopharmaceutical company operating a growing contract devel

EFFECT - Scinai Immunotherapeutics Ltd. (0001611747) (Filer)

F-1 - Scinai Immunotherapeutics Ltd. (0001611747) (Filer)

6-K - Scinai Immunotherapeutics Ltd. (0001611747) (Filer)

Nasdaq confirms compliance with Listing Rule 5550(a)(2) after 19 consecutive business days with a closing bid price at or above $1.00; minimum bid price matter is closed JERUSALEM, Sept. 21, 2026 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (NASDAQ:SCNI) ("Scinai" or the "Company"), a biopharmaceutical company combining innovative immunology therapeutic development with a revenue-generating contract development and manufacturing organization ("CDMO"), today announced that it has received written notification from Nasdaq Listing Qualifications confirming that the Company has regained compliance with the $1.00 minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2) and that the m

6-K - Scinai Immunotherapeutics Ltd. (0001611747) (Filer)

Following the conclusion of the PinCell option and license arrangements, Scinai concentrates resources on its NanoAb platform and CDMO commercial execution, without taking on additional PC111 funding commitments JERUSALEM, Sept. 8, 2026 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (NASDAQ:SCNI) ("Scinai" or the "Company"), a biopharmaceutical company combining innovative immunology therapeutic development with a revenue-generating contract development and manufacturing organization ("CDMO"), today announced a strategic refocusing of its R&D portfolio following the conclusion of its option and license arrangements with PinCell S.r.l. relating to PC111.

EFFECT - Scinai Immunotherapeutics Ltd. (0001611747) (Filer)

POS AM - Scinai Immunotherapeutics Ltd. (0001611747) (Filer)

6-K - Scinai Immunotherapeutics Ltd. (0001611747) (Filer)

Investor webinar scheduled for August 26, 2026 at 11:00 a.m. EDTJERUSALEM, Aug. 24, 2026 /PRNewswire/ – Scinai Immunotherapeutics Ltd. (NASDAQ:SCNI) ("Scinai" or the "Company"), a biopharmaceutical company combining innovative therapeutic development with a revenue-generating contract development and manufacturing organization ("CDMO"), today provided a corporate update and reported financial results for the six months ended June 30, 2026.  Corporate HighlightsCommitted Customer Orders1 reached approximately $3.1 million as of August 16, 2026, of which approximately $2.1 million had been invoiced.The Company is progressing an expanded clinical manufacturing and CMC program for a U.S.-based b

6-K - Scinai Immunotherapeutics Ltd. (0001611747) (Filer)

Appointment strengthens operational infrastructure and supports integration and scale-up of Scinai's expanded CDMO platform.JERUSALEM, Aug. 10, 2026 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (NASDAQ:SCNI) ("Scinai" or the "Company"), a biopharmaceutical company advancing a pipeline of innovative inflammation and immunology therapeutics, today announced that its wholly owned subsidiary, Scinai Biopharma Services Ltd., a contract development and manufacturing organization (CDMO), has appointed Mr. Eran Kuratz as Head of Supply Chain and Business Process Administration. Mr. Kuratz reports directly to Scinai Chief Executive Officer Amir Reichman.

4 - Scinai Immunotherapeutics Ltd. (0001611747) (Issuer)

4 - Scinai Immunotherapeutics Ltd. (0001611747) (Issuer)

6-K - Scinai Immunotherapeutics Ltd. (0001611747) (Filer)

6-K - Scinai Immunotherapeutics Ltd. (0001611747) (Filer)

JERUSALEM, June 10, 2026 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (NASDAQ:SCNI), ("Scinai" or the "Company"), a biopharmaceutical company combining innovative therapeutic development with a revenue-generating CDMO subsidiary, today reported financial results for the three months ended March 31, 2026 and provided a corporate update. Corporate HighlightsCompleted the acquisition of Recipharm Israel, expanding the Company's CDMO platform through the addition of a second manufacturing site in Yavne, Israel, and establishing a strategic commercial collaboration with global CDMO leader Recipharm AB.Advanced multiple non-dilutiv

6-K - Scinai Immunotherapeutics Ltd. (0001611747) (Filer)

JERUSALEM, May 20, 2026 /PRNewswire/ – Scinai Immunotherapeutics Ltd. (NASDAQ:SCNI), ("Scinai" or the "Company"), a biopharmaceutical company advancing a pipeline of innovative inflammation and immunology therapeutics, today announced that its wholly owned subsidiary, Scinai Biopharma Services Ltd., a contract development and manufacturing organization (CDMO), has appointed Mr. Eilon Elmalem as Site Head of its Yavne CDMO facility, effective June 14, 2026. Mr. Elmalem has worked with Scinai over the past two years as an external consultant and has supported the Company's CDMO activities and operational development efforts. More recently, he has been involved in the transition and operational